 Selecta Biosciences Inc NASDAQ: SELB announced top-line results from the Phase 1 study evaluating the ImmTOR platform to mitigate the formation of neutralizing antibodies against an adeno-associated viral serotype 8 AAV8 serotype capsid used in gene therapies. At day 30, in subjects administered a single 0.3 mgkg dose of ImmTOR, Selecta observed a median anti-AAV8 neutralizing antibody titer of 1:5, a 250-fold lower level than subjects dosed with AAV8 capsid alone. 